Unraveling the Molecular Inhibition and Conformational Changes of Hsp70 and Hsc70 Induced by VER-155008, a

Maria Caroline Barbosa da Silva1, Carlos Gefferson Silva Falabelo2, Elvis Santos Leonardo3

  • 1Laboratório de Simulação Computacional, Instituto de Biodiversidade, Universidade Federal do Oeste do Pará, Rua Vera Paz, Salé s/n, 68040-255 Santarém, Pará, Brazil.

ACS Omega
|January 5, 2026
PubMed

Insights

Heat shock protein 70 kDa (Hsp70) aids cancer cell survival and chemotherapy resistance. This study reveals how VER-155008 inhibits Hsp70 by inducing a half-open conformation, offering insights for developing targeted cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Heat shock protein 70 kDa (Hsp70) is crucial for cancer cell survival and chemotherapy resistance by inhibiting apoptosis.
  • Hsp70's structural similarity to Hsc70 complicates the development of selective Hsp70 inhibitors.
  • VER-155008 is a known nonselective Hsp70 inhibitor that competitively inhibits adenosine triphosphate (ATP) binding.

Purpose of the Study:

  • To investigate the conformational dynamics of Hsp70 and Hsc70 in the presence of the inhibitor VER-155008.
  • To elucidate the binding mechanism of VER-155008 and its effect on ATP binding.
  • To identify molecular characteristics for developing novel, selective Hsp70 inhibitors for cancer therapy.

Main Methods:

  • Molecular dynamics (MD) simulations.
  • Free energy landscape (FEL) analysis.

Main Results:

  • VER-155008 induces a half-open conformation in Hsp70 and Hsc70, inhibiting ATP binding.
  • Key residues (Ser275, Lys271, Glu268) were identified as crucial for stabilizing inhibitor binding and conformational states.
  • The study provides a molecular understanding of VER-155008's inhibitory action.

Conclusions:

  • The findings elucidate VER-155008's mechanism of action on Hsp70 and Hsc70.
  • Identified molecular characteristics can guide the design of selective Hsp70 inhibitors.
  • This research advances the development of targeted cancer therapies by focusing on Hsp70 inhibition.